<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042142</url>
  </required_header>
  <id_info>
    <org_study_id>230279</org_study_id>
    <nct_id>NCT04042142</nct_id>
  </id_info>
  <brief_title>Glucagon Resistance in Patients With NAFLD</brief_title>
  <official_title>In-depth Studies of Glucagon Resistance on Hepatic Glucose, Fatty Acid and Triglyceride Kinetics and Generation of Toxic Lipid Intermediates in NAFLD and NASH.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Council for Independent Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is
      impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis
      (NASH). Moreover, they propose a dys-coordinated, reduced glucagon sensitivity in hepatic
      lipid metabolism and endogen glucose production in patients with NAFLD and NASH compared with
      healthy subjects and patients with simple steatosis. This reduced sensitivity may be the
      basis of a more severe dyslipidemia and the production of increased concentrations of toxic
      lipid intermediates in plasma and muscle tissue. The study will include healthy subjects with
      obesity and subjects with simple steatosis and NASH, tested at basal glucagonemia and
      moderate hyperglucagonemia to mimic insulin resistant levels during simultaneous somatostatin
      infusion and replacement doses of insulin and growth hormone. Infusion of palmitate,
      VLDL-triglyceride and glucose tracers in combination with indirect calorimetry as well as
      skeletal and adipose tissue biopsies will be employed to assess free fatty acid and
      VLDL-triglyceride kinetics (turnover, and oxidation) and hepatic fatty acid-esterification.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VLDL-triglyceride kinetics (appearance rate (µmol/min) and oxidation (µmol/min))</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>Ex vivo labeled VLDL [14C]-triolein tracer technique. Oxidation is measured by specific activity in exhaled air.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogen glucose production (mmol/kg/min)</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>3-3H glucose tracer technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LPL-activity (lipoprotein lipase, µmol/h)</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>Measured by the 'glycerol-stabilized substrate' method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-triglyceride-fatty acid uptake in muscle and fatty tissue (%)</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>Measurement of fatty acid concentration and specific activity in muscle- and adipose tissue biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of relevant genes in tissues</measure>
    <time_frame>30 minutes at steady-state</time_frame>
    <description>PCR in muscle- and adipose tissue biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid turnover (µmol/min)</measure>
    <time_frame>30 minutesat steady-state</time_frame>
    <description>Infusion af [9,10-3H] palmitate and measurement of specific activity in muscle and adipose tissue</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Healthy overweight subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MR spectroscopy verified no steatosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with non-alcoholic fatty liver disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MR spectroscopy verified steatosis, no steatohepatitis on liver biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with non-alcoholic steatohepatitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MR spectroscopy verified steatosis, steatohepatitis on liver biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glucagon</intervention_name>
    <description>Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.</description>
    <arm_group_label>Healthy overweight subjects</arm_group_label>
    <arm_group_label>Subjects with non-alcoholic fatty liver disease</arm_group_label>
    <arm_group_label>Subjects with non-alcoholic steatohepatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 28 kg/m2

          -  steatosis FF% &gt; 5,6% on MR spectroscopy for NAFLD and NASH groups

        Exclusion Criteria:

          -  active smoking

          -  pregnancy

          -  comorbidity other than hypertension and hyperlipidemia

          -  participation in other radioactive isotope studies within the past 3-5 months
             (depending on radiation dose)

          -  blood donation (within 3 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Heebøll</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Heebøll, MD, Ph.D</last_name>
    <phone>27338050</phone>
    <email>saraheeb@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Danmark</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Heebøll</last_name>
      <phone>27338050</phone>
      <email>saraheeb@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

